PubMed

미국에서 약물치료 반응성 근성 발작에 대한 vagus 신경 자극을 보조 치료로 사용하는 경제적 평가

PMID: 36691763 · 2023

C, h, r, i, s, t, o, p, h, e, r, , R, a, s, p, i, n, ;, , E, d, w, a, r, d, , F, a, u, g, h, t, ;, , J, e, a, n, n, e, , A, r, m, a, n, d, ;, , F, r, a, n, c, e, s, c, a, , B, a, r, i, o, n, ;, , V, i, c, k, i, , P, o, l, l, i, t, ;, , J, o, a, n, n, a, , M, u, r, p, h, y, ;, , V, a, n, e, s, s, a, , D, a, n, i, e, l, s, o, n

학술지Journal of medical economics

연도2023

PMID36691763

초록

People with recurrent epileptic seizures are typically treated with anti-seizure medications (ASMs). Around a third of epilepsy patients fail to achieve an adequate response to ASMs and may be eligible to receive vagus nerve stimulation (VNS) therapy for their drug-resistant epilepsy (DRE) if they are unsuited to surgery. VNS received approval from the United States (US) Food and Drug Administration agency. However, there has to date been no comprehensive cost effectiveness evaluation of VNS wit

공식 출처

PubMed에서 보기 →

데이터는 PubMed / NCBI에서 제공됩니다. 전문과 최신 정보는 반드시 공식 기록을 확인하세요.